Jounce Therapeutics, Inc.

Delisted

CIK 0001640455Non-AcceleratedSmaller ReportingBiological Products, (No Diagnostic Substances)DelawareFY ends Dec 31

Period

FY 2022

Revenue

—

Net Income

$-50.92M

Total Assets

$212.55M

Equity

$183.11M

Shares Out

52.14M

Op. Cash Flow

$-28.88M

Business

Jounce Therapeutics, Inc. is a former operating company in Biological Products, (No Diagnostic Substances), incorporated in Delaware. Securities are no longer actively traded on a major U.S. exchange.

Auto-generated from company profile

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31
License and collaboration revenuerelated party	82	27	62	148	65
Research and development	103	89	79	67	70
General and administrative	31	29	29	28	26
Total operating expenses	134	118	107	95	96
Operating loss	−52	−91	−45	53	−31
Other income, net	1	199,000	1	4	4
Loss before provision for income taxes	−51	−91	−44	57	−27
Provision for income taxes	135,000	15,000	14,000	46,000	46,000
Net loss	−51	−91	−44	57	−27
Net loss per share, basic (in dollars per share)	−0.99	−1.82	−1.24	1.72	−0.84
Net loss per share, diluted (in dollars per share)	−0.99	−1.82	−1.24	1.66	−0.84
Weighted-average common shares outstanding, basic (in shares)	52	50	35	33	33
Weighted-average common shares outstanding, diluted (in shares)	52	50	35	34	33
Unrealized loss on available-for-sale securities	−439,000	−221,000	−71,000	132,000	331,000
Comprehensive loss	−51	−91	−44	57	−27

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31
Cash and cash equivalents	151	96	147	53	48
Short-term investments	39	83	59	116	142
Prepaid expenses and other current assets	8	12	5	5	2
Total current assets	197	191	211	174	192
Property and equipment, net	4	5	7	11	14
Long-term investments	0	42	7	2	6
Operating lease right-of-use asset	9	12	15	18	20
Other non-current assets	3	3	4	2	3
Total assets	213	253	244	206	214
Accounts payable	2	2	2	2	3
Accrued expenses	17	13	12	9	7
Operating lease liability, current	4	4	3	3	3
Other current liabilities	178,000	62,000	42,000	132,000	104,000
Total current liabilities	24	19	19	14	66
Operating lease liability, net of current portion	6	10	14	17	20
Total liabilities	29	29	33	31	110
Commitments and contingencies (Note 13)	—	—	—	—	—
Preferred stock, $0.001 par value: 5,000 shares authorized at December 31, 2022 and 2021; no shares issued or outstanding at December 31, 2022 and 2021	0	0	0	0	0
Common stock, $0.001 par value: 160,000 shares authorized at December 31, 2022 and 2021; 51,694 and 51,265 shares issued at December 31, 2022 and 2021, respectively; 51,694 and 51,265 shares outstanding at December 31, 2022 and 2021, respectively	51,000	51,000	42,000	34,000	33,000
Additional paid-in capital	477	466	362	282	268
Accumulated other comprehensive loss	−677,000	−238,000	−17,000	54,000	−78,000
Accumulated deficit	−293	−242	−151	−107	−164
Total stockholders equity	183	224	211	175	104
Total liabilities and stockholders equity	213	253	244	206	214

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31
Stock-based compensation expense	10	11	10	10	9
Depreciation expense	2	3	3	4	4
Net amortization of premiums and discounts on investments	903,000	921,000	47,000	−1	−1
Gain on sale of property and equipment	−103,000	0	—	—	0
Prepaid expenses and other current assets	5	−7	−236,000	−1	—
Other non-current assets	451,000	490,000	−1	−728,000	0
Accounts payable	421,000	−329,000	−296,000	−944,000	562,000
Accrued expenses and other current liabilities	4	1	3	2	−1
Deferred revenuerelated party	0	−2	2	−98	−65
Other liabilities	−387,000	−189,000	−142,000	4,000	107,000
Net cash used in operating activities	−29	−83	−28	−30	−64
Purchases of investments	−25	−130	−86	−189	−253
Proceeds from maturities of investments	109	70	137	221	337
Purchases of property and equipment	−919,000	−373,000	−94,000	−985,000	−1
Net cash provided by (used in) by investing activities	83	−61	51	31	86
Proceeds from at the market offering, net of issuance costs	0	91	14	4	0
Proceeds from exercise of stock options	442,000	1	600,000	437,000	2
Net cash provided by financing activities	442,000	92	71	4	2
Net increase (decrease) in cash, cash equivalents and restricted cash	55	−52	94	5	24
Purchases of property and equipment in accounts payable and accrued expenses	14,000	0	0	29,000	31,000
Stock option exercise receivables in prepaid expenses and other current assets	0	50,000	0	—	—
Cash paid for lease liabilities	5	5	4	4	0
Cash paid for income taxes	17,000	8,000	45,000	101,000	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Jounce Therapeutics, Inc.'s CIK number?

Jounce Therapeutics, Inc.'s SEC CIK number is 0001640455 (1640455). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Jounce Therapeutics, Inc.'s SEC filings?

All of Jounce Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

Look up any company's CIK number →